RHYTHM PHARMACEUTICALS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$104.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$49.30M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$55.64M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$47.51M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$52.90M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$196.54M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$260.60M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$184.68M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$181.12M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$49.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$104.94M 10-Q · filed 2026-08-04 | -$152.44M derived: sum of 3 quarters · filed 2026-08-04 | -$205.35M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | -$55.64M 10-Q · filed 2026-05-05 | -$103.14M derived: sum of 2 quarters · filed 2026-05-05 | -$156.05M derived: sum of 3 quarters · filed 2026-05-05 | -$202.68M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | -$47.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$100.41M derived: sum of 2 quarters · filed 2026-02-26 | -$147.04M derived: sum of 3 quarters · filed 2026-08-04 | -$196.54M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$52.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$99.54M derived: sum of 2 quarters · filed 2026-08-04 | -$149.03M 10-Q · filed 2025-11-04 | -$192.33M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | -$46.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$96.13M 10-Q · filed 2026-08-04 | -$139.42M derived: sum of 3 quarters · filed 2026-08-04 | -$183.10M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | -$49.50M 10-Q · filed 2026-05-05 | -$92.79M derived: sum of 2 quarters · filed 2026-05-05 | -$136.47M derived: sum of 3 quarters · filed 2026-05-05 | -$168.73M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | -$43.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$86.97M derived: sum of 2 quarters · filed 2026-02-26 | -$119.23M derived: sum of 3 quarters · filed 2026-02-26 | -$260.60M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$43.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$75.94M derived: sum of 2 quarters · filed 2025-11-04 | -$217.31M 10-Q · filed 2025-11-04 | -$258.94M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$32.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$173.63M 10-Q · filed 2025-08-05 | -$215.27M derived: sum of 3 quarters · filed 2026-02-26 | -$259.43M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$141.37M 10-Q · filed 2025-05-07 | -$183.00M derived: sum of 2 quarters · filed 2026-02-26 | -$227.17M derived: sum of 3 quarters · filed 2026-02-26 | -$273.87M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$41.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$85.80M derived: sum of 2 quarters · filed 2026-02-26 | -$132.50M derived: sum of 3 quarters · filed 2026-02-26 | -$184.68M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$44.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$90.87M derived: sum of 2 quarters · filed 2024-11-06 | -$143.04M 10-Q · filed 2024-11-06 | -$185.54M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | -$46.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$98.88M 10-Q · filed 2024-08-06 | -$141.38M derived: sum of 3 quarters · filed 2025-02-28 | -$182.24M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | -$52.18M 10-Q · filed 2024-05-07 | -$94.67M derived: sum of 2 quarters · filed 2025-02-28 | -$135.53M derived: sum of 3 quarters · filed 2025-02-28 | -$180.53M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$42.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$83.35M derived: sum of 2 quarters · filed 2025-02-28 | -$128.35M derived: sum of 3 quarters · filed 2025-02-28 | -$181.12M 10-K · filed 2025-02-28 | |
| 2022-09-30 | -$40.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$85.86M derived: sum of 2 quarters · filed 2023-11-08 | -$138.63M 10-Q · filed 2023-11-08 | -$181.49M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | -$45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$97.77M 10-Q · filed 2023-08-01 | -$140.63M derived: sum of 3 quarters · filed 2024-02-29 | -$175.74M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | -$52.76M 10-Q · filed 2023-05-02 | -$95.63M derived: sum of 2 quarters · filed 2024-02-29 | -$130.74M derived: sum of 3 quarters · filed 2024-02-29 | -$166.13M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | -$42.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$77.97M derived: sum of 2 quarters · filed 2024-02-29 | -$113.36M derived: sum of 3 quarters · filed 2024-02-29 | -$69.61M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$35.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$70.50M derived: sum of 2 quarters · filed 2022-11-08 | -$26.75M 10-Q · filed 2022-11-08 | -$61.64M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$35.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $8.36M 10-Q · filed 2022-08-03 | -$26.54M derived: sum of 3 quarters · filed 2023-03-01 | -$60.35M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $43.75M 10-Q · filed 2022-05-03 | $8.85M derived: sum of 2 quarters · filed 2023-03-01 | -$24.96M derived: sum of 3 quarters · filed 2023-03-01 | -$56.08M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$34.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$68.71M derived: sum of 2 quarters · filed 2023-03-01 | -$99.83M derived: sum of 3 quarters · filed 2023-03-01 | -$134.00M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$33.82M 10-Q · filed 2020-11-02 | -$64.94M derived: sum of 2 quarters · filed 2020-11-02 | -$99.10M 10-Q · filed 2021-11-02 | -$99.10M 10-Q · filed 2020-11-02 | -$132.06M derived: sum of 4 quarters · filed 2021-05-03 |
| 2020-06-30 | -$31.12M 10-Q · filed 2020-11-02 | -$65.28M 10-Q · filed 2021-08-03 | -$98.24M derived: sum of 3 quarters · filed 2021-05-03 | -$134.24M derived: sum of 4 quarters · filed 2021-05-03 | |
| 2020-03-31 | -$34.16M 10-Q · filed 2021-05-03 | -$67.12M derived: sum of 2 quarters · filed 2021-05-03 | -$103.12M derived: sum of 3 quarters · filed 2021-05-03 | -$145.92M derived: sum of 4 quarters · filed 2021-05-03 | |
| 2019-12-31 | -$32.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$68.96M derived: sum of 2 quarters · filed 2021-03-01 | -$111.75M derived: sum of 3 quarters · filed 2021-03-01 | -$140.73M 10-K · filed 2021-03-01 | |
| 2019-09-30 | -$36.00M 10-Q · filed 2020-11-02 | -$78.80M derived: sum of 2 quarters · filed 2020-11-02 | -$107.77M 10-Q · filed 2020-11-02 | -$133.28M derived: sum of 4 quarters · filed 2020-11-02 | |
| 2019-06-30 | -$42.80M 10-Q · filed 2020-11-02 | -$71.77M 10-Q · filed 2020-08-03 | -$97.28M derived: sum of 3 quarters · filed 2020-11-02 | -$114.96M derived: sum of 4 quarters · filed 2020-11-02 | |
| 2019-03-31 | -$28.97M 10-Q · filed 2020-11-02 | -$54.48M derived: sum of 2 quarters · filed 2020-11-02 | -$72.17M derived: sum of 3 quarters · filed 2020-11-02 | -$86.58M derived: sum of 4 quarters · filed 2020-11-02 | |
| 2018-12-31 | -$25.51M 10-K · filed 2019-03-08 | -$43.19M derived: sum of 2 quarters · filed 2019-11-01 | -$57.60M 10-Q · filed 2019-05-03 | -$74.06M 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$17.69M 10-Q · filed 2019-11-01 | -$32.10M derived: sum of 2 quarters · filed 2019-11-01 | -$48.56M 10-Q · filed 2019-11-01 | -$59.09M derived: sum of 4 quarters · filed 2019-11-01 | |
| 2018-06-30 | -$14.41M 10-Q · filed 2019-11-01 | -$30.87M 10-Q · filed 2019-07-29 | -$41.40M derived: sum of 3 quarters · filed 2019-11-01 | -$51.42M derived: sum of 4 quarters · filed 2019-11-01 | |
| 2018-03-31 | -$16.46M 10-Q · filed 2019-11-01 | -$26.99M derived: sum of 2 quarters · filed 2019-11-01 | -$37.01M derived: sum of 3 quarters · filed 2019-11-01 | -$43.81M derived: sum of 4 quarters · filed 2019-11-01 | |
| 2017-12-31 | -$10.53M 10-K · filed 2019-03-08 | -$20.55M derived: sum of 2 quarters · filed 2019-03-08 | -$27.35M derived: sum of 3 quarters · filed 2019-03-08 | -$33.71M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$10.02M 10-K · filed 2019-03-08 | -$16.82M derived: sum of 2 quarters · filed 2019-03-08 | -$23.18M 10-Q · filed 2018-11-09 | -$31.54M derived: sum of 4 quarters · filed 2019-03-08 | |
| 2017-06-30 | -$6.80M 10-K · filed 2019-03-08 | -$13.16M 10-Q · filed 2018-08-08 | -$21.53M derived: sum of 3 quarters · filed 2019-03-08 | -$27.92M derived: sum of 4 quarters · filed 2019-03-08 | |
| 2017-03-31 | -$6.36M 10-K · filed 2019-03-08 | -$14.73M derived: sum of 2 quarters · filed 2019-03-08 | -$21.12M derived: sum of 3 quarters · filed 2019-03-08 | -$26.85M derived: sum of 4 quarters · filed 2019-03-08 | |
| 2016-12-31 | -$8.37M 8-K · filed 2018-11-09 | -$14.76M derived: sum of 2 quarters · filed 2018-11-09 | -$20.49M derived: sum of 3 quarters · filed 2018-11-09 | -$25.87M 10-K · filed 2019-03-08 | |
| 2016-09-30 | -$6.39M 8-K · filed 2018-11-09 | -$12.12M derived: sum of 2 quarters · filed 2018-11-09 | -$17.51M 10-Q · filed 2017-11-14 | ||
| 2016-06-30 | -$5.73M 8-K · filed 2018-11-09 | -$11.12M derived: sum of 2 quarters · filed 2018-11-09 | |||
| 2016-03-31 | -$5.38M 8-K · filed 2018-11-09 | ||||
| 2015-12-31 | -$11.07M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |